MedRhythms, a company engaged in developing prescription digital therapeutics that use sensors, software, and music to measure and improve walking for patients with a neurologic injury or disease, announced today the closing of a $25 million Series B financing round co-led by Morningside Ventures and Advantage Capital, with participation from existing investor Werth Family Investment Associates. The company has raised a total of $34 million in gross proceeds from private financings since inception. Read more.
MedRhythms Closes $25M Series B Funding Led by Morningside Ventures and Advantage Capital
